Jayanta Bhattacharya says the US biomedical agency can’t continue ‘business as usual’ if it wants to restore its reputation.

Building scientific capacity in the global south is key to solving today’s most pressing planetary challenges.

Options are emerging for the tens of millions of people who stop taking GLP-1 drugs because of side effects, cost or ...